Medical Affairs PharmD Fellowship 2018 - 2020 Alkermes plc is a fully At Alkermes plc, our employees consistently strive to provide physicians and patients with integrated, global bio- treatment options that address important unmet needs. Through our scientific expertise, pharmaceutical company proprietary technologies and global resources, we are uniquely positioned to continue building a portfolio of medicines for major clinical conditions with a focus on central nervous system focused on developing (CNS) disorders. innovative medicines that address the unmet Our success to date is evident from our diverse commercial product portfolio, including treatments in major diseases, such as , addiction, diabetes and multiple needs and challenges sclerosis. Beyond our commercial products, we have a promising pipeline of proprietary of people living with drug candidates, many in late-stage development. Both our commercialized products and serious, chronic diseases. rich pipeline demonstrate our leadership in drug development for CNS diseases, a therapeutic area where we have established expertise and a promise for delivering new treatments.

Our Proprietary Products Products Using Alkermes Technologies Our commercial product portfolio reflects We have granted licenses under our proprietary technologies WEBSITE www.alkermes.com our years of experience in developing to enable third parties to develop, commercialize and, in

TICKER SYMBOL innovative and patient-inspired solutions. some cases, manufacture products for which we receive NASDAQ: ALKS These unique products address patient royalties and/or manufacturing revenues.

HEADQUARTERS needs in major disease areas. ® Connaught House AMPYRA (dalfampridine) is a twice-daily, controlled- 1 Burlington Road ARISTADA® () extended- release tablet indicated as a treatment to improve walking Dublin 4, Ireland release injectable suspension is indicated in patients with multiple sclerosis. AMPYRA is approved in +353 1 772 8000 for the treatment of schizophrenia. It is the the U.S. where it is marketed by , Inc. EMPLOYEES first long-acting with Inc. holds the rights to develop and commercialize Approximately 1,900 WW once-monthly, six-week and once-every-two- the medication in all markets outside the U.S., where it is CONTACTS ® Corporate Communications months dosing options. sold under the trade name FAMPYRA . Voice: +1 781 609 6143 ® ® VIVITROL ( for extended-release BYDUREON (exenatide extended-release for injectable Blair Jackson injectable suspension) is an extended- suspension) is a once-weekly therapy for the treatment of Senior Vice President, Business Development release injectable formulation of naltrexone. type 2 diabetes. BYDUREON is marketed in the U.S. and Voice: +1 781 609 6594 It is the first and only non-narcotic, non- EU by AstraZeneca. addictive, once-monthly medication for both INVEGA SUSTENNA® ( palmitate), a Janssen alcohol and opioid dependence. Designed product, is a once-monthly injectable form of paliperidone for once-monthly dosing, VIVITROL (INVEGA®) indicated for the treatment of schizophrenia eliminates the need for patients to make a and schizoaffective disorder. INVEGA SUSTENNA is daily decision about taking their medicine. commercialized under the trade name XEPLION® in the EU. Alkermes commercializes VIVITROL in the U.S. Janssen Pharmaceuticals is responsible INVEGA TRINZA® (paliperidone palmitate), a Janssen for the commercialization of VIVITROL product, is a three-month injectable form of paliperidone in Russia and the Commonwealth of (INVEGA®) indicated for the treatment of schizophrenia. Independent States. INVEGA TRINZA is commercialized under the trade name TREVICTA® in the EU. RISPERDAL CONSTA® (), a Janssen product, is a long-acting injectable form of Janssen’s schizophrenia drug risperidone (RISPERDAL®). It is administered once every two weeks for the management of schizophrenia and bipolar I disorder. RISPERDAL CONSTA is commercialized by Janssen in more than 90 countries. Medical Affairs PharmD Fellowship

Description

This new 2-year Doctor of Pharmacy Fellowship Program will support the Medical Affairs team at Alkermes located in Waltham, MA. A partnership with this fellowship with Northeastern University Bouvé College of Health Sciences is currently being developed. Alkermes Medical Affairs strives to educate healthcare communities and decision makers on the value of our products through the generation and dissemination of scientifically rigorous, accurate, and unbiased clinical, economic, and health outcomes information, with the goal of advancing healthcare. We accomplish this by partnering with internal Alkermes colleagues to catalyze science and knowledge and by serving as a bridge between Alkermes and the healthcare community.

Objectives

]] Understand various roles, processes and industry standards involved in the creation and dissemination of medical information in the setting

]] Strategically planning, developing and training on standard response letters

]] Contribute to the review of internal promotional and medical materials

]] Work closely with Medical Affairs team to develop training and scientific education for internal and external stakeholders

]] Collaborate with cross-functional teams (regulatory, marketing, sales, legal, clinical development) to provide and communicate the most up to date scientific information as a subject matter expert

]] Create, manage and track strategic scientific communication plans in a cross-functional manner

]] Partner with Medical Directors to develop scientific materials that align with the scientific communication materials that align with the scientific communication plan (e.g. manuscripts, abstracts, posters, slide decks)

Requirements (Deadline December 1, 2017)

]] Curriculum vitae (CV) and cover letter

]] Unofficial college transcript

]] Three references’ contact information and formal letters of recommendation (per request)

]] Candidates must have a Doctor of Pharmacy degree from an ACPE-accredited college of pharmacy by June 30, 2018

How to Apply

Candidates who wish to apply must submit their curriculum vitae (CV), cover letter, and unofficial college transcript. If attending ASHP MidYear Clinical Meeting this material should be submitted through PPS. Applications will be reviewed on a rolling basis until December 1, 2017.

Contact

For further questions, please email [email protected]

CLINICAL DEVELOPMENT PROGRAMS

At Alkermes plc, we approach the development of new therapeutics with a thoughtful focus on patients’ real-world needs. We are committed to providing patients and caregivers with medicines that offer benefits in terms of safety, efficacy and ultimately, improved health outcomes. This is illustrated by our focused and growing pipeline. Phase 3 FDA Review Preclinical Phase 1 Phase 2 CANDIDATE

ALKS 5461 (Major Depressive Disorder) Aripiprazole Lauroxil NanoCrystal® Dispersion (Intiation product for ARISTADA®)

ALKS 3831 (Schizophrenia)

ALKS 8700 (Multiple Sclerosis)

ALKS 6428 (Transition From Opioid Dependence*)

ALKS 4230 (Immuno-oncology)

*Transition From Physical Dependence on Opioids to VIVITROL®

At Northeastern, we encourage our students to become engaged citizens of the world, confident, and resourceful people who realize that their knowledge and actions have positive effects on their own lives and those of others. Students ignite their passion for learning and are exposed to the endless possibilities around them through transformative experiential education. The School of Pharmacy provides a dynamic academic environment to guide and support Fellows toward successful careers in the biopharmaceutical industry and offers the opportunity to gain teaching and research experiences in an academic setting. The Northeastern faculty and Alkermes Fellowship preceptors mentor Fellows according to the Fellows’ scholarly and professional interests throughout the two-year program. As a visiting scholar at the School of Pharmacy, a Fellow will: • Teach and coordinate courses and facilitate seminars and laboratories • Create and publish scholarly research and review articles • Present research at scientific and clinical meetings • Collaborate with fellows and residents in the Boston area

AMPYRA® and FAMPYRA® are registered trademarks of Acorda Therapeutics, Inc. ARISTADA® is a trademark of Alkermes Pharma Ireland Limited. BYDUREON® is a registered trademark of , LLC. RISPERDAL®, RISPERDAL CONSTA®, INVEGA®, INVEGA SUSTENNA®, XEPLION®, INVEGA TRINZA® and TREVICTA® are registered trademarks of Johnson & Johnson. VIVITROL® is a registered trademark of Alkermes, Inc.